Similarly, rituximab has shown favorable outcomes in patients with rapidly progressive ILD, particularly in those with anti-melanoma differentiation-associated protein 5 (MDA-5) dermatomyositis-associated ILD [43]. This evidence concerns the gene IFIH1 and interstitial lung disease.